Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D in Childhood Growth, Bone and Muscle: Full Evidence Review

Previous related pageVitamin D in Childhood Growth, Bone and Muscle: Study SummaryNext related pageVitamin D in Childhood Growth, Bone and Muscle: Study Summary
Study at a glance

What was studied?

Do vitamin D supplements improve growth, bone or muscle outcomes in children?

What did the studies find?

Four separate trials changed vitamin D blood status without consistently demonstrating better height, strength or measured bone outcomes. One trial also lowered a calcium-regulating hormone without an overall added bone-mineral benefit. A partly accessible bone report described mixed findings.

What does this mean?

A change in a blood test or hormone does not automatically mean that a child grows more or becomes stronger. The result depends on the children, the intervention and the outcome measured.

What are the limits?

Some bone evidence could not be assessed fully, including the D-pro bone paper and a Mongolian fracture report. The review does not show that all bone studies agree or that treating clinical deficiency is unnecessary. Research schedules are not personal supplement advice.

Read the full article below ↓

Vitamin D studies in growing children ask several different questions. A supplement may change a blood measurement without making children taller, increasing their strength or adding measurable bone mineral. This review compares four independent trial populations and separates those outcomes. It also identifies important bone evidence that we could inspect only partly, so the review should not be read as a complete assessment of every skeletal result. For the shorter account, read Vitamin D in Childhood Growth, Bone and Muscle: Study Summary.

For current UK guidance, including advice for children, see the NHS page Vitamin D.

What counts as a change in growth or physiology?

The main blood measurement is 25-hydroxyvitamin D, usually written as 25(OH)D. It indicates circulating vitamin D status. It is different from vitamin D3 in a supplement and from the active hormone, 1,25-dihydroxyvitamin D. An increase in this measurement demonstrates a response in status. It does not, by itself, show what happened inside a child’s bone or muscle. For the distinction between circulating exposure and a cellular response system, see Vitamin D Receptors.

The studies also measured different parts of growth. Height describes linear growth. Bone mineral content is the amount of mineral estimated in the scanned region. Bone mineral density relates that amount to a measure of the scanned bone’s size. These are related measurements, but they are not interchangeable. A difference in one skeletal region need not appear elsewhere, and a change in a scan is not automatically a reduction in fractures. The measurement distinctions are developed in Bone Mineralisation, Turnover and Fractures Measure Different Outcomes.

Muscle strength and physical performance add another distinction. Grip strength tests one task; jumping and leg pressing test others. An estimated measure of exercise capacity is different again. A trial can answer a specific question about a measured task without establishing every aspect of muscle development. The broader physiological setting is introduced in Vitamin D and Muscle Function.

Parathyroid hormone, or PTH, provides an endocrine measurement. It is a hormone involved in calcium regulation. A change in PTH can help describe the physiological response to supplementation, but it cannot substitute for directly measuring growth or bone. The South African trial below is particularly useful because it measured both hormonal and skeletal responses. Vitamin D and Bone provides the wider skeletal context; the trials below supply population-specific evidence.

The amounts below describe monitored research interventions, not a supplement plan for a child. IU means international units. Micrograms are another unit used to describe the quantity of vitamin D. Daily and weekly schedules should not be treated as interchangeable instructions, and these studies do not establish an individual child’s treatment needs.

Mongolia: a substantial change in status without a strength advantage

Ganmaa and colleagues studied 8,851 children aged six to 13 in 18 Mongolian schools. Children were assigned to vitamin D or a matched placebo for three years. The vitamin D group received 14,000 IU weekly. The large trial and masked comparison provide a stronger test of this intervention than simply comparing children who happen to have different blood results (Ganmaa et al., 2024).

Starting status was low. The average season-adjusted 25(OH)D concentration was 29.7 nmol/L, and 95.5% were below 50 nmol/L. Nanomoles per litre, shortened to nmol/L, describe a concentration in blood. At three years, the reported concentrations were 77.4 nmol/L in the vitamin D group and 26.7 nmol/L in the placebo group. The intervention therefore produced a substantial separation in the measurement being targeted.

That separation did not produce a corresponding overall advantage in measured muscle strength or exercise outcomes. The adjusted three-year grip-strength difference was 0.01 kg, with a 95% confidence interval from −0.21 to 0.23 kg. This interval describes the uncertainty around the estimated average difference. It includes both a small negative and a small positive difference; it does not support a meaningful claim that the supplemented group became stronger on this test.

The other overall muscle and exercise comparisons were also not improved. Subgroup analyses that accounted for multiple comparisons did not establish an advantage. This matters because a large trial can generate many possible comparisons. Selecting an isolated favourable result after examining several subgroups can make chance variation look more convincing than it is.

There are limits to the conclusion. These were secondary outcomes of the parent trial. Some exercise assessments involved subsets, and oxygen uptake was estimated rather than directly measured in every child. The protocol amendment history also means that all these outcomes should not be described as having been fixed before enrollment. Children with rickets were excluded, so the result is not a test of treating established rickets or symptomatic deficiency.

A separate report from the same Mongolian trial examined fractures. We identified that report but did not inspect its complete principal paper. This review therefore does not use it to make a detailed fracture-prevention claim. The fully assessed muscle report and the incompletely assessed fracture report must remain separate sources, even though they describe one underlying trial population.

South Africa: a hormone response without added bone mineral

The ViDiKids trial enrolled 1,682 children aged six to 11 in 23 South African schools. It compared 10,000 IU of vitamin D weekly with placebo for three years. A bone substudy included 450 children, with a mean age of about ten; 391 had follow-up scans. Unlike the Mongolian population, low vitamin D status was relatively uncommon in this substudy (Middelkoop et al., 2024).

Average starting 25(OH)D was approximately 70 nmol/L, and 5.8% were below 50 nmol/L. Supplementation increased status and reduced PTH. The adjusted PTH difference was −0.55 pmol/L, with a 95% confidence interval from −0.94 to −0.17 pmol/L. Picomoles per litre are the concentration unit used for this hormone result.

The hormonal difference did not translate into an overall increase in the measured bone mineral content. For the whole body excluding the head, the adjusted difference was −8.0 g, with a confidence interval from −30.7 to 14.7 g. At the lumbar spine, the difference was −0.3 g, with an interval from −1.3 to 0.8 g. These estimates did not demonstrate an added mineral advantage from the tested supplement schedule.

The distinction is physiologically informative. The body responded to the intervention in a circulating measurement and in a regulatory hormone, while the scans did not show a corresponding overall benefit. It would be misleading to describe the trial simply as showing “no response”. It would be equally misleading to treat the lower PTH as proof of stronger bones.

Fractures were uncommon: 17 were reported across the comparison. The estimated odds ratio was 0.70, but its confidence interval ran from 0.27 to 1.85. That wide interval does not establish fracture prevention, and it also does not exclude an important difference. The small number of events is central to understanding this outcome.

A companion report examined growth in the same trial. The adjusted difference in height-for-age was −0.08 standardised units, with an interval from −0.19 to 0.03. Standardised measurements express position relative to an age-based reference. The study did not demonstrate improved height growth from the intervention. This companion is additional information about ViDiKids, not a second independent trial.

Diet and selection also matter. Calcium intake was low, but the intervention did not include an assigned calcium supplement. Children with clinical rickets, HIV or certain chronic illnesses were excluded. The findings therefore concern the studied population and nutritional setting. They cannot establish that a child with clinical mineral deficiency or another disease would respond in the same way. For a comparison separating developmental animal models, endocrine responses and adult fracture outcomes, see Vitamin D and Bone: Mineralisation, Cell Signalling and Fractures: Full Study; those experiments are not additional childhood trials.

Denmark: muscle findings and incompletely assessed bone findings

The D-pro trial enrolled 200 healthy Danish children aged six to eight. Over 24 winter weeks, it compared vitamin D with placebo while also comparing higher: and normal-protein yogurt. This is a factorial design: two interventions are studied within the same experiment. The vitamin D tablets were labelled as providing 20 micrograms daily; analysis of the tablets found about 25 micrograms. The vitamin D comparison was masked, but the yogurt comparison was not (Thams et al., 2022).

The muscle analysis began with an average 25(OH)D concentration of 79.6 nmol/L. Vitamin D helped preserve winter status, but the study did not detect an overall improvement in strength or physical function. The estimated grip difference was 0.1 kg, with an interval from −0.3 to 0.6 kg. The leg-press difference was 38 newtons, with an interval from −61 to 136 newtons. Newtons measure force.

A suggested sex difference needs particular care. A comparison between boys and girls receiving vitamin D is not the same as showing that vitamin D benefits girls compared with girls receiving placebo. The latter comparison did not establish a clear benefit. The evidence does not justify advertising a proven strength advantage for girls.

Missing measurements also affect interpretation. Grip and leg-strength measurements were available for more children than the jumping and sit-to-stand tests; pandemic disruption reduced some endpoint samples. The results concern secondary outcomes in a healthy, largely sufficient population. They are not a direct test of treating weakness caused by severe deficiency. For a separate explanation of why a change in muscle-cell development is not itself a strength result, see Vitamin D, Cell Fate and Tissue Structure: Full Evidence Review.

The companion bone paper reported a different pattern across skeletal measures: its primary total-body-less-head bone-density outcome was null, while some secondary bone measures were positive. We could inspect only its abstract and parts of the indexed principal report, not the complete methods, tables and supporting analyses. Those missing details prevent a full assessment of the secondary findings and their qualifications (Stounbjerg et al., 2021).

This limitation changes the conclusion of the present review. The D-pro bone results cannot be silently omitted to create an all-null account of childhood skeletal trials. They also cannot be presented as fully assessed evidence of a broad skeletal benefit. The accessible material indicates mixed results; the complete reliability and interpretation of those results remain incompletely assessed here. The muscle report was read in full and can support the narrower muscle conclusions above.

A short Northern Irish trial: several outcomes, limited precision

Royle and colleagues assigned 118 children aged four to 11 to a daily vitamin D3 spray providing 10 micrograms or to placebo for 12 weeks. The main report describes 102 completers, with missing endpoint values carried forward from baseline for 16 children. This differs from wording in the abstract suggesting that all 118 completed (Royle et al., 2026).

The intervention increased 25(OH)D: the adjusted between-group difference was 11.72 nmol/L, with an interval from 5.96 to 17.75 nmol/L. Exploratory muscle and bone-related laboratory outcomes did not show a statistically supported advantage after accounting for multiple comparisons. These measurements add useful information, but the trial was primarily designed around vitamin D status rather than powered to resolve each functional outcome.

The family structure is another limitation. Siblings were included and families were assigned together, while the analyses treated children individually without a reported adjustment for this clustering. Children from one household may share characteristics that make their measurements less independent than those of unrelated participants. Missing data were also uneven between groups, and the follow-up was short.

This study therefore supports a cautious statement: a short intervention changed status without establishing additional muscle or bone-related benefit in the measured exploratory outcomes. It cannot settle long-term growth, skeletal development or fracture prevention. Its findings should be considered alongside the larger and longer trials, rather than given the same precision simply because each report contributes one study.

What the comparisons establish and what remains missing

The four trial populations demonstrate why starting status, duration and outcome choice belong in the interpretation. Mongolia tested a long intervention in children with substantially lower status. ViDiKids tested a long intervention in a largely sufficient bone substudy. D-pro examined winter responses and muscle function in healthy Danish children. Royle’s study provided a shorter, smaller comparison with several exploratory measures.

These differences prevent a simple dose ranking across studies. The trials did not randomly assign children between countries, diets, age ranges or schedules. Comparing their supplement amounts alone would discard the conditions that determine what each result means. The studies also do not identify a universal blood concentration at which every child’s growth or strength is optimal. Three years of treatment does not establish that an effect persists after treatment ends; this distinction is examined in Vitamin D and Lasting Gene Regulation: Full Evidence Review.

The strongest common lesson is about interpretation: changing vitamin D status does not automatically demonstrate improved height, strength or bone mineral measurements. ViDiKids further shows that a hormonal response can occur without an overall added bone-mineral advantage. These findings are compatible with uncertainty about other populations and outcomes; they do not establish that vitamin D is physiologically unimportant.

The bone assessment remains incomplete. The D-pro principal bone report and supporting analyses were only partly accessible, and the Mongolian fracture paper was not fully assessed. Mixed D-pro findings are therefore retained as a limitation, while detailed fracture conclusions from the unread Mongolian report are excluded. The available evidence supports careful, outcome-specific conclusions, not a claim that all skeletal trials agree or that supplementation has no place in clinical deficiency care.

Scientific sources

Not reportedInfluence of vitamin D supplementation on muscle strength and exercise capacity in Mongolian schoolchildren: secondary outcomes from a randomised controlled trial. Ganmaa D et al. BMJ Open Sport & Exercise Medicine. 2024;10:e002018. DOI:10.1136/bmjsem-2024-002018.

Not reportedInfluence of vitamin D supplementation on bone mineral content, bone turnover markers, and fracture risk in South African schoolchildren: multicenter double-blind randomized placebo-controlled trial (ViDiKids). Middelkoop K et al. Journal of Bone and Mineral Research. 2024;39:211 to 221. DOI:10.1093/jbmr/zjae007.

Not reportedInfluence of vitamin D supplementation on growth, body composition, pubertal development and spirometry in South African schoolchildren: a randomised controlled trial (ViDiKids). Middelkoop K et al. BMJ Paediatrics Open. 2024. DOI:10.1136/bmjpo-2024-002495.

Not reportedVitamin D supplementation and increased dairy protein intake do not affect muscle strength or physical function in healthy 6 to 8-year-old children: the D-pro randomized trial. Thams L et al. European Journal of Nutrition. 2022;61:3613 to 3623. DOI:10.1007/s00394-022-02912-0.

Not reportedThe Effect of Vitamin D3 Supplementation on Vitamin D Status and Associated Health Outcomes in Children: A Randomized Controlled Trial. Royle E et al. Journal of Nutrition. 2026;156:101493. DOI:10.1016/j.tjnut.2026.101493.

Not reportedEffects of vitamin D and high dairy protein intake on bone mineralization and linear growth in 6: to 8-year-old children: the D-pro randomized trial. Stounbjerg NG et al. American Journal of Clinical Nutrition. 2021;114:1971 to 1985. DOI:10.1093/ajcn/nqab286. Abstract and indexed sections only; complete principal paper and material supplement not assessed.

Not reportedVitamin D supplements for fracture prevention in schoolchildren in Mongolia: analysis of secondary outcomes from a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes & Endocrinology. 2024;12:29 to 38. DOI:10.1016/S2213-8587(23)00317-0. Identified companion report; complete principal paper not assessed and detailed fracture conclusions not drawn here.

Related reading

Original sources

Source

Vitamin D

For current UK guidance, including advice for children, see the NHS page Vitamin D.

Publication details

For current UK guidance, including advice for children, see the NHS page Vitamin D.

Read more →
Source

Influence of vitamin D supplementation on muscle strength and exercise capacity in Mongolian schoolchildren: secondary outcomes from a randomised controlled trial

Multicentre, randomised, placebo-controlled clinical trial conducted in children aged 6 to 13 years at baseline attending 18 schools in Ulaanbaatar.

Publication details

Not reportedInfluence of vitamin D supplementation on muscle strength and exercise capacity in Mongolian schoolchildren: secondary outcomes from a randomised controlled trial. Ganmaa D et al. BMJ Open Sport & Exercise Medicine. 2024;10:e002018. DOI:10.1136/bmjsem-2024-002018.

Read more →
Source

Influence of vitamin D supplementation on bone mineral content, bone turnover markers, and fracture risk in South African schoolchildren: multicenter double-blind randomized placebo-controlled trial (ViDiKids)

Randomized controlled trials (RCTs) to determine the influence of vitamin D on BMC and fracture risk in children of Black African ancestry are lacking.

Publication details

Not reportedInfluence of vitamin D supplementation on bone mineral content, bone turnover markers, and fracture risk in South African schoolchildren: multicenter double-blind randomized placebo-controlled trial (ViDiKids). Middelkoop K et al. Journal of Bone and Mineral Research. 2024;39:211 to 221. DOI:10.1093/jbmr/zjae007.

Read more →
Source

Influence of vitamin D supplementation on growth, body composition, pubertal development and spirometry in South African schoolchildren: a randomised controlled trial (ViDiKids)

A second potential limitation relates to the fact that pubertal status was assessed by participants themselves, rather than by health professionals, whose judgement may be more objective.

Publication details

Not reportedInfluence of vitamin D supplementation on growth, body composition, pubertal development and spirometry in South African schoolchildren: a randomised controlled trial (ViDiKids). Middelkoop K et al. BMJ Paediatrics Open. 2024. DOI:10.1136/bmjpo-2024-002495.

Read more →
Source

Vitamin D supplementation and increased dairy protein intake do not affect muscle strength or physical function in healthy 6–8-year-old children: the D-pro randomized trial

Published in Thams L et al. European Journal of Nutrition (2022).

Publication details

Not reportedVitamin D supplementation and increased dairy protein intake do not affect muscle strength or physical function in healthy 6 to 8-year-old children: the D-pro randomized trial. Thams L et al. European Journal of Nutrition. 2022;61:3613 to 3623. DOI:10.1007/s00394-022-02912-0.

Read more →
Source

Effects of vitamin D and high dairy protein intake on bone mineralization and linear growth in 6- to 8-year-old children: the D-pro randomized trial

Published in Stounbjerg NG et al. American Journal of Clinical Nutrition (2021).

Publication details

Not reportedEffects of vitamin D and high dairy protein intake on bone mineralization and linear growth in 6: to 8-year-old children: the D-pro randomized trial. Stounbjerg NG et al. American Journal of Clinical Nutrition. 2021;114:1971 to 1985. DOI:10.1093/ajcn/nqab286. Abstract and indexed sections only; complete principal paper and material supplement not assessed.

Read more →
Source

Vitamin D supplements for fracture prevention in schoolchildren in Mongolia: analysis of secondary outcomes from a multicentre, double-blind, randomised, placebo-controlled trial

Published in Lancet Diabetes & Endocrinology (2024).

Publication details

Not reportedVitamin D supplements for fracture prevention in schoolchildren in Mongolia: analysis of secondary outcomes from a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes & Endocrinology. 2024;12:29 to 38. DOI:10.1016/S2213-8587(23)00317-0. Identified companion report; complete principal paper not assessed and detailed fracture conclusions not drawn here.

Read more →